Publications

Park K, Tomlins SA, Mudaliar KM, Chiu Y-L, Esgueva R, Mehra R, Suleman K, Varambally S, Brenner JC, MacDonald T et al..  2010.  Antibody-based detection of ERG rearrangement-positive prostate cancer.. Neoplasia. 12(7):590-8.

Rickman DS, Chen Y-B, Banerjee S, Pan Y, Yu J, Vuong T, Perner S, Lafargue CJ, Mertz KD, Setlur SR et al..  2010.  ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.. Neoplasia. 12(12):1031-40.

Perner S, Svensson MA, Hossain RR, Day JR, Groskopf J, Slaughter RC, Jarleborn AR, Hofer MD, Kuefer R, Demichelis F et al..  2010.  ERG rearrangement metastasis patterns in locally advanced prostate cancer.. Urology. 75(4):762-7.

Sboner A, Habegger L, Pflueger D, Terry S, Chen DZ, Rozowsky JS, Tewari AK, Kitabayashi N, Moss BJ, Chee MS et al..  2010.  FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data.. Genome Biol. 11(10):R104.

Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, Perner S, Adami H-O, Fall K, Mucci LA et al..  2010.  Molecular sampling of prostate cancer: a dilemma for predicting disease progression.. BMC Med Genomics. 3:8.

Esgueva R, Perner S, LaFargue CJ, Scheble V, Stephan C, Lein M, Fritzsche FR, Dietel M, Kristiansen G, Rubin MA.  2010.  Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort.. Mod Pathol. 23(4):539-46.

Demichelis F, Setlur SR, Beroukhim R, Perner S, Korbel JO, Lafargue CJ, Pflueger D, Pina C, Hofer MD, Sboner A et al..  2009.  Distinct genomic aberrations associated with ERG rearranged prostate cancer.. Genes Chromosomes Cancer. 48(4):366-80.

Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA.  2009.  ETS gene fusions in prostate cancer: from discovery to daily clinical practice.. Eur Urol. 56(2):275-86.

Hofer MD, Kuefer R, Maier C, Herkommer K, Perner S, Demichelis F, Paiss T, Vogel W, Rubin MA, Hoegel J.  2009.  Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer.. Cancer Res. 69(2):640-6.

Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M et al..  2009.  Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol. 27(21):3459-64.

Pflueger D, Rickman DS, Sboner A, Perner S, Lafargue CJ, Svensson MA, Moss BJ, Kitabayashi N, Pan Y, de la Taille A et al..  2009.  N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.. Neoplasia. 11(8):804-11.

Mosquera J-M, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT et al..  2009.  Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.. Clin Cancer Res. 15(14):4706-11.

Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, Kuefer R, Tewari AK, Setlur SR, Demichelis F et al..  2009.  SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.. Cancer Res. 69(7):2734-8.

Mertz KD, Demichelis F, Sboner A, Hirsch MS, Dal Cin P, Struckmann K, Storz M, Scherrer S, Schmid DM, Strebel RT et al..  2008.  Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer.. Int J Cancer. 123(3):569-76.

Mosquera J-M, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, Paris PL, Simko J, Bismar TA, Ayala G et al..  2008.  Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications.. Clin Cancer Res. 14(11):3380-5.

Kelly KA, Setlur SR, Ross R, Anbazhagan R, Waterman P, Rubin MA, Weissleder R.  2008.  Detection of early prostate cancer using a hepsin-targeted imaging agent.. Cancer Res. 68(7):2286-91.

Perner S, Wagner PL, Demichelis F, Mehra R, Lafargue CJ, Moss BJ, Arbogast S, Soltermann A, Weder W, Giordano TJ et al..  2008.  EML4-ALK fusion lung cancer: a rare acquired event.. Neoplasia. 10(3):298-302.

Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andrén O, Johnson LA et al..  2008.  Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.. J Natl Cancer Inst. 100(11):815-25.

Demichelis F, Greulich H, Macoska JA, Beroukhim R, Sellers WR, Garraway L, Rubin MA.  2008.  SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines.. Nucleic Acids Res. 36(7):2446-56.

Rubin MA.  2008.  Targeted therapy of cancer: new roles for pathologists--prostate cancer.. Mod Pathol. 21 Suppl 2:S44-55.

Mertz KD, Demichelis F, Kim R, Schraml P, Storz M, Diener P-A, Moch H, Rubin MA.  2007.  Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer.. Hum Pathol. 38(10):1454-62.

Setlur SR, Royce TE, Sboner A, Mosquera J-M, Demichelis F, Hofer MD, Mertz KD, Gerstein M, Rubin MA.  2007.  Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer.. Cancer Res. 67(21):10296-303.

Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S, Tchinda J, Laxman B, Vessella RL, Beroukhim R et al..  2007.  Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.. Neoplasia. 9(3):200-6.

Cohen RJ, Wheeler TM, Bonkhoff H, Rubin MA.  2007.  A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma.. Arch Pathol Lab Med. 131(7):1103-9.

Perner S, Hofer MD, Kim R, Shah RB, Li H, Möller P, Hautmann RE, Gschwend JE, Kuefer R, Rubin MA.  2007.  Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.. Hum Pathol. 38(5):696-701.